Loading
companiesCompany
Duality Biotherapeutics
Chinese ADC platform company behind BioNTech's trastuzumab pamirtecan (BNT323/DB-1303) and AI-nominated targets.
Also called: DualityBio Inc.
Overview
Duality Biotherapeutics, based in Shanghai and listed in Hong Kong as 9606.HK, is the Chinese antibody-drug conjugate platform company behind BioNTech's trastuzumab pamirtecan, also known as BNT323 or DB-1303, and a set of targets nominated with artificial intelligence. DB-1303 targets HER2 and is in a phase 3 in endometrial cancer with BioNTech, DB-1311 targets B7-H3, DB-1329 targets CDCP1, a target identified by AI, and all rest on its DITAC linker-payload platform. OnCo links it to HER2 and B7-H3 as targets. Whether AI-nominated ADC targets outperform the crowded conventional ones is the question DB-1329 will test. The HER2 and B7-H3 target pages carry the field context.
Headquarters
Shanghai, CN
Scorecard
All companies#370of 1244 companies, score 10
- phase 3 +3
- targets +2
- modalities +2
- registry trials +3
0 approved, 1 in phase 3, 0 earlier, 1 targets, 2 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2024-12 | Duality Biotherapeutics to Avenzo Therapeutics DB-1418 (AVZO-1418), EGFR x HER3 bispecific ADC | Licence | $50m | up to $1.15bn | source |
| 2023-04-03 | Duality Biotherapeutics to BioNTech DB-1303 (HER2 ADC, later BNT323) and DB-1311 (B7-H3 ADC, BNT324) | Licence | $170m | more than $1.5bn | source |
Type
Biotech · 9606.HK
Stage
Public
Website
Phase 3Antibody-drug conjugate (anti-HER2 antibody, topoisomerase I inhibitor payload)
Trastuzumab pamirtecan is DualityBio and BioNTech's HER2 antibody-drug conjugate, in phase 3 trials in breast cancers with high and with modest HER2 expression and in HER2-expressing endometrial cancer.
Similar pages
- TreatmentBNT324
Shares A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer, A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors, DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors, B7-H3.
- CompanyBioNTech
Shares A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer, A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors, DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors, First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors.
- TreatmentPM8002
Shares A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer, DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors, First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors, A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer.
- CompanyMyricx Bio
- IdeaAlpha radioligands after ADC failure
- TermOverexpression
- IdeaDeliver CAR-T cells straight into the fluid around the brain
- IdeaRe-map the tumour's surface proteins before choosing the next antibody drug
fronts
targets
drugs
Phase 3Antibody-drug conjugate (anti-HER2 antibody, topoisomerase I inhibitor payload)
trials
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast CancerA Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung CancerA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsA Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsA Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-BreA Study of DB-1310 in Advanced/Metastatic Solid TumorsA Study of DB-1324 in Advanced/Metastatic Gastrointestinal TumorsA Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast CancerDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid TumorsFirst-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid TumorsFirst-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors